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Introduction {#jcsm12145-sec-0005}
============

Cachexia is a complex wasting syndrome characterized by systemic inflammation and progressive loss of skeletal muscle mass (muscle wasting). Many diseases can cause cachexia including cancer, AIDS, sepsis, diabetes, chronic renal failure, congestive heart failure, and chronic obstructive pulmonary disease. Cachexia contributes significantly to the morbidity and mortality of patients with these diseases.[1](#jcsm12145-bib-0001){ref-type="ref"} Although it has become clear that cachectic muscle wasting is primarily caused by accelerated muscle protein degradation, the precise mechanism through which the catabolic pathways in muscle are remotely activated by diseases in disparate locations is still undefined.[2](#jcsm12145-bib-0002){ref-type="ref"}

In various diseases, abnormal increase of certain humoral factors can activate the cellular pathways for protein degradation in muscle, including inflammatory cytokines such as tumour necrosis factor alpha (TNFα), interleukin (IL)‐6, IL‐1β, and TNF‐like weak inducer of apoptosis, glucocorticoids, lipopolysaccharide (LPS), and cancer‐released factors such as proteolysis‐inducing factor.[3](#jcsm12145-bib-0003){ref-type="ref"} The breakdown of myofibrillar proteins is thought mediated mainly by the ubiquitin--proteasome pathway (UPP), which is capable of targeting specific proteins via E3 ubiquitin ligases.[4](#jcsm12145-bib-0004){ref-type="ref"} At least three E3s, atrogin1 (MAFbx),[5](#jcsm12145-bib-0005){ref-type="ref"}, [6](#jcsm12145-bib-0006){ref-type="ref"} MuRF1,[6](#jcsm12145-bib-0006){ref-type="ref"} and UBR2 (E3α‐II),[7](#jcsm12145-bib-0007){ref-type="ref"}, [8](#jcsm12145-bib-0008){ref-type="ref"} are up‐regulated in cachectic muscle in various disease models, which are rate limiting for UPP‐mediated muscle protein degradation and considered as markers of muscle catabolism. In addition, the autophagy--lysosome pathway (ALP) is activated in cachectic muscle,[9](#jcsm12145-bib-0009){ref-type="ref"}, [10](#jcsm12145-bib-0010){ref-type="ref"}, [11](#jcsm12145-bib-0011){ref-type="ref"} which may mediate the loss of organelles including mitochondria and cytosolic proteins.[12](#jcsm12145-bib-0012){ref-type="ref"} These two cellular proteolytic systems are often coordinately activated by diverse catabolic stimuli in a stimulus‐dependent manner. For example, fasting, denervation, or disuse inactivates Akt, resulting in activation of FoxO transcription factors to increase the activity of both the UPP and ALP.[13](#jcsm12145-bib-0013){ref-type="ref"}, [14](#jcsm12145-bib-0014){ref-type="ref"} On the other hand, inflammatory conditions and oxidative stress activate the UPP and ALP through the activation of p38 mitogen‐activated protein kinases (MAPK).[15](#jcsm12145-bib-0015){ref-type="ref"}, [16](#jcsm12145-bib-0016){ref-type="ref"}, [17](#jcsm12145-bib-0017){ref-type="ref"} At least three isoforms of the p38 MAPK family are expressed in skeletal muscle. The α‐isoform is well established as an epigenetic regulator essential for the initiation of myogenesis,[18](#jcsm12145-bib-0018){ref-type="ref"}, [19](#jcsm12145-bib-0019){ref-type="ref"} whereas the γ isoform regulates the expansion of myogenic precursor cells,[20](#jcsm12145-bib-0020){ref-type="ref"} endurance exercise‐induced mitochondrial biogenesis and angiogenesis,[21](#jcsm12145-bib-0021){ref-type="ref"} and glucose uptake.[22](#jcsm12145-bib-0022){ref-type="ref"} On the contrary, the β‐isoform appears responsible for the catabolic effect of p38 MAPK because of its activation of transcription factor C/EBPβ[23](#jcsm12145-bib-0023){ref-type="ref"} that up‐regulates atrogin1[24](#jcsm12145-bib-0024){ref-type="ref"} and UBR2.[8](#jcsm12145-bib-0008){ref-type="ref"} In addition, Smad2/3 transcription factors that are activated by the TGFβ family of cytokines including activins and myostatin promote muscle protein breakdown.[25](#jcsm12145-bib-0025){ref-type="ref"} Thus, identifying the signalling pathway that mediates muscle catabolism by a particular stimulus is important for both mechanistic and therapeutic considerations.

Recent data indicate that activation of ActRIIB by its agonists, activins or myostatin, may cause muscle wasting associated with various diseases.[25](#jcsm12145-bib-0025){ref-type="ref"} Activin A is a major form of the activins. Normally, activin A serves as an endocrine factor to stimulate FSH biosynthesis and secretion in the pituitary gland.[26](#jcsm12145-bib-0026){ref-type="ref"} In many catabolic disease states, circulating activin A levels rise as a paracrine/autocrine factor generated by activated macrophages[27](#jcsm12145-bib-0027){ref-type="ref"} or certain types of cancer cells.[28](#jcsm12145-bib-0028){ref-type="ref"} Myostatin is predominantly expressed in skeletal muscle and secreted from muscle cells as a paracrine/autocrine factor.[29](#jcsm12145-bib-0029){ref-type="ref"} Similar to activin A, myostatin may also be synthesized and released by certain cancer cells and thus contributes to cancer‐induced muscle wasting.[30](#jcsm12145-bib-0030){ref-type="ref"}, [31](#jcsm12145-bib-0031){ref-type="ref"} Therefore, several drugs that antagonize ActRIIB activity have been developed and are in clinical trials for the treatment of various forms of muscle atrophy. However, the signalling mechanism through which ActRIIB mediates muscle catabolism is poorly understood. ActRIIB belongs to the TGFβ receptor superfamily and activates Smad2/3 signalling that promotes muscle catabolism.[32](#jcsm12145-bib-0032){ref-type="ref"} This led to a popular belief that the Smad2/3 signalling pathway is responsible for ActRIIB‐mediated muscle catabolism.[25](#jcsm12145-bib-0025){ref-type="ref"} However, recent data revealed that Smad3 knockout in mice does not spare the mice from muscle atrophy induced by the ActRIIB agonist myostatin,[33](#jcsm12145-bib-0033){ref-type="ref"} suggesting that Smad2/3 signalling is non‐essential for ActRIIB‐mediated muscle catabolism. As a member of the TGFβ receptor superfamily, ActRIIB activation in muscle cells leads to activation of TAK‐1,[34](#jcsm12145-bib-0034){ref-type="ref"} a kinase that activates a cascade of kinases resulting in the activation of p38 MAPK.[35](#jcsm12145-bib-0035){ref-type="ref"} Given that the activation of p38β MAPK mediates up‐regulation of E3 ligases atrogin1 and UBR2 through the transcription factor C/EBPβ,[8](#jcsm12145-bib-0008){ref-type="ref"}, [23](#jcsm12145-bib-0023){ref-type="ref"}, [24](#jcsm12145-bib-0024){ref-type="ref"} we hypothesized that ActRIIB mediates muscle catabolism through the p38β MAPK‐signalling pathway. In the current study, we tested this hypothesis and found evidence that ActRIIB‐mediated activation of muscle catabolic pathways is dependent on p38β MAPK.

Materials and methods {#jcsm12145-sec-0006}
=====================

Myogenic cell culture {#jcsm12145-sec-0007}
---------------------

Murine C2C12 myoblasts (American Type Culture Collection) were cultured in growth medium (Dulbecco\'s modified eagle\'s medium supplemented with 10% foetal bovine serum) at 37°C with 5% CO~2~. At 85--90% confluence, myoblast differentiation was induced by incubation for 96 h in differentiation medium (Dulbecco\'s modified eagle\'s medium supplemented with 4% heat‐inactivated horse serum) to form myotubes. Myotubes were treated with activin A or myostatin (3 ng/mL) for indicated time and replaced every 24 h. Pretreatment of SB202190 or SP600125 (10 μM, dissolved in DMSO with 0.1% final concentration, Sigma‐Aldrich, St. Louis, MO) for 30 min was carried out when indicated. All cell culture experiments were independently replicated three times as indicated (*N* = 3).

Animal use {#jcsm12145-sec-0008}
----------

Experimental protocols were approved in advance by the institutional Animal Welfare Committee at the University of Texas Health Science Center at Houston. Mice with muscle‐specific knockout of p38β (p38β MKO) were created by crossbreeding floxed‐p38β mice (p38β^f/f^) in C57BL/6 background[21](#jcsm12145-bib-0021){ref-type="ref"} with muscle creatine kinase‐Cre (MCK‐Cre, The Jackson Laboratory, Bar Harbor, ME). Loss of the *p38β* gene was previously shown not affecting muscle phenotype.[21](#jcsm12145-bib-0021){ref-type="ref"} Activin A dissolved in phosphate‐buffered saline (PBS) was intraperitoneally (i.p.) injected into 7‐week‐old male mice (0.1 mg/kg) with PBS as control. SB202190 was i.p. injected (5 mg/kg) 30 min prior to activin A as needed. Tibialis anterior (TA) was collected in 8 h after activin A injection for analyses from six mice per group.

Transfection of small interfering RNA {#jcsm12145-sec-0009}
-------------------------------------

Predesigned small interfering RNAs (siRNAs) specific for p38α and p38β were purchased from Sigma‐Aldrich. The IDs of p38α and p38β were SASI_Mm01_00020743 and SASI_Mm01_00044863, respectively. Control siRNA was purchased from Ambion (Austin, TX). These siRNAs were introduced into C2C12 myoblasts using the jetPRIME reagent (Polyplus‐transfection Inc., Illkirch, France) according to the manufacturer\'s protocol. In 24 h, myoblasts were differentiated, and experiments were started in another 96 h when myotubes were formed. Because of the role of p38α MAPK in promoting myogenic differentiation, we observed a delay in differentiation in p38α MAPK‐knockdown cells during the early stage (first 48 h). However, differentiation in these cells caught up later, and at 96 h, there was no significant difference in myotube formation between control and p38α knockdown cells. Knockdown of p38β MAPK did not alter differentiation.

Real‐time PCR {#jcsm12145-sec-0010}
-------------

Total RNA was isolated from myotubes or muscle by using TRIzol reagent (Invitrogen, Carlsbad, CA). Real‐time PCR was performed as described previously.[24](#jcsm12145-bib-0024){ref-type="ref"} Sequences of specific primers are atrogin1 (sense: 5′‐CACATTCTCT‐CCTGGAAGGGC‐3′, antisense: 5′‐TTGATAAAGTCTTGAGGGGAAAGTG‐3′); UBR2 (sense: 5′‐TATTCTCCTCCTTACCTTG‐3′, antisense: 5′‐CGAAACCGCTCTTGGCATA‐3′); LC3b (sense: 5′‐CGTCCTGGACAAGACCAAGT‐3′, antisense: 5′‐ATTGCTGTCCCGAATGTCTC‐3′); and glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) (sense: 5′‐CATGGCCTTCCGTGTTCCTA‐3′, antisense: 5′‐GCGGCACGTCAGATCCA‐3′). Data were normalized to GAPDH.

Western blot analysis {#jcsm12145-sec-0011}
---------------------

Western blot analysis was carried out as described previously.[16](#jcsm12145-bib-0016){ref-type="ref"} Antibodies to total and/or phosphorylated p38MAPK (T181/Y182), p‐C/EBPβ (Thr‐188), Akt (S‐473), and total p38α and p38β were from Cell Signaling Technology (Beverly, MA). Antibody to total C/EBPβ was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to atrogin1/MAFbx was from ECM Biosciences (Versailles, KY). Antibodies to UBR2 and LC3‐II were obtained from Novus Biologicals (Littleton, CO). Anti‐myosin heavy chain (MHC) antibody (MF‐20) was from R&D Systems (Minneapolis, MN). Data were normalized to α‐tubulin (antibody was from Development Studies Hybridoma Bank at the University of Iowa, Iowa City, IA).

Fluorescence microscopy {#jcsm12145-sec-0012}
-----------------------

C2C12 myotubes were stained with anti‐MHC antibody (MF‐20) and fluorescein isothiocyanate‐conjugated secondary antibody and examined using a Zeiss Axioskop 40 microscope and a Zeiss Axiocam MRM camera system controlled by Axiovision Release 4.6 imaging software. Acquired images were analysed for myotube diameter using the method of Menconi *et al.* [36](#jcsm12145-bib-0036){ref-type="ref"} with modifications. Briefly, myotube diameters were measured in a total of 100 myotubes from ≥10 random fields using computerized image analysis (Scion Image, Frederick, MD, USA) at three points along their length. The average of diameters at the three points was used for each myotube. The measurements were conducted in a masked fashion.

Statistical analysis {#jcsm12145-sec-0013}
--------------------

Data were analysed with one‐way analysis of variance using the SigmaStat software (Systat Software, San Jose, CA) as indicated. When applicable, control samples from independent experiments were normalized to a value of 1 without showing variations (actual variations were within a normal range). A *P*‐value \< 0.05 was considered to be statistically significant. Data are presented as the mean ± standard error.

Results {#jcsm12145-sec-0014}
=======

Activin A activates the p38β MAPK‐C/EBPβ catabolic signalling and the Akt anabolic signalling in C2C12 myotubes {#jcsm12145-sec-0015}
---------------------------------------------------------------------------------------------------------------

To investigate the catabolic signalling pathways activated by ActRIIB in muscle cells, we treated C2C12 myotubes with endotoxin‐free recombinant activin A, the major agonist of ActRIIB, and monitored its downstream signalling events. Through a preliminary study involving multiple doses, we observed that 3 ng/mL of activin A provoked a robust yet non‐plateaued catabolic response in myotubes (data not shown). Using this concentration, we observed that activin A activated p38 MAPK and its effector C/EBPβ (phosphorylation of Thr‐188) at 1 h (*Figure* [1](#jcsm12145-fig-0001){ref-type="fig"}A). For comparison, we also monitored Akt activity by measuring the phosphorylation state of its S‐473 residue, which inversely regulates muscle catabolism through FoxO1/3.[37](#jcsm12145-bib-0037){ref-type="ref"}, [38](#jcsm12145-bib-0038){ref-type="ref"} Levels of pS473‐Akt were increased by activin A, similar to previous observations in myotubes treated with tumour cell conditioned medium[24](#jcsm12145-bib-0024){ref-type="ref"} or TNFα.[39](#jcsm12145-bib-0039){ref-type="ref"} To determine whether activin A induces C/EBPβ and Akt activation through p38 MAPK, myotubes were pre‐treated with p38α/β MAPK inhibitor SB202190, which prevented activation of C/EBPβ but not Akt (*Figure* [1](#jcsm12145-fig-0001){ref-type="fig"}A). To verify the specificity of SB202190 inhibition of C/EBPβ activation, additional experiment was performed by pre‐treating myotubes with c‐Jun N‐terminal kinase (JNK) inhibitor SP600125, which did not alter activin A‐induced C/EBPβ activation (*Figure* [1](#jcsm12145-fig-0001){ref-type="fig"}B). Then, we treated myotubes with another ActRIIB agonist myostatin and observed similar activation of p38 MAPK, C/EBPβ, and Akt (*Figure* [1](#jcsm12145-fig-0001){ref-type="fig"}C). Thus, the activin A effects observed are attributable to ActRIIB activation. Further, by knocking down the expression of p38α MAPK or p38β MAPK utilizing specific siRNAs, we confirmed that p38β MAPK, not p38α MAPK, mediates C/EBPβ activation induced by activin A (*Figure* [1](#jcsm12145-fig-0001){ref-type="fig"}D). These data indicate that ActRIIB activation by activin A or myostatin rapidly activates both p38 MAPK and Akt in myotubes in a parallel fashion. Given that Akt activation inhibits muscle catabolism, Akt does not appear to be part of activin A‐activated catabolic signalling. On the contrary, the p38β MAPK*‐*C/EBPβ signalling pathway appears involved in activin A‐induced catabolic signalling.

![Activin A activates the p38β mitogen‐activated protein kinases (MAPK)‐C/EBPβ catabolic signalling and the Akt anabolic signalling in C2C12 myotubes. (A) Activin A activates p38 MAPK‐C/EBPβ and Akt signalling. C2C12 myotubes were treated with activin A (Act A, 3 ng/mL) and/or SB202190 (SB, 10 μM) for 1 h as indicated, and cell lysate was analysed by Western blotting. (B) JNK inhibitor SP600125 does not block activin A activation of C/EBPβ. SP600125 (SP, 10 μM) was used as in the place of SB in (A), and its effect on C/EBPβ activation was analysed. (C) Myostatin activates p38 MAPK‐C/EBPβ and Akt signalling. C2C12 myotubes were treated with myostatin (3 ng/mL) and/or SB202190 (SB, 10 μM) for 1 h as indicated, and cell lysate was analysed by Western blotting. (D) p38β MAPK specifically mediates C/EBPβ activation by activin A. C2C12 myoblasts transfected with siRNA as indicated were differentiated for 96 h to form myotubes and then treated with activin A for 1 h. Cell lysate was analysed by Western blotting. Data were analysed with analysis of variance. Asterisk (\*) denotes a difference (*P* \< 0.05).](JCSM-8-202-g001){#jcsm12145-fig-0001}

Activin A up‐regulates the expression of E3 ubiquitin ligases and activates autophagy through the activation of p38β MAPK in C2C12 myotubes {#jcsm12145-sec-0016}
-------------------------------------------------------------------------------------------------------------------------------------------

Next, we investigated the signalling mechanism through which activin A up‐regulates E3 ubiquitin ligases that are implicated in muscle catabolism, that is, atrogin1, MuRF1, and UBR2. We found that activin A treatment of myotubes for 8 h increased the levels of all three E3s. In addition, the up‐regulation of atrogin1 and UBR2 was blocked by SB202190. However, the up‐regulation of MuRF1 was not affected by the p38 MAPK inhibitor (*Figure* [2](#jcsm12145-fig-0002){ref-type="fig"}A). To verify the specificity of the SB202190 effect on atrogin1 and UBR2 levels, additional experiment was performed by pre‐treating myotubes with JNK inhibitor SP600125, which did not alter activin A‐induced up‐regulation of the two ligases (*Figure* [2](#jcsm12145-fig-0002){ref-type="fig"}B). Utilizing siRNA‐mediated gene knocked down, we confirmed that the p38β MAPK isoform mediated activin A up‐regulation of atrogin1 and UBR2, but not MuRF1 (*Figure* [2](#jcsm12145-fig-0002){ref-type="fig"}C). To determine whether p38β MAPK mediates activin A‐induced up‐regulation of atrogin1 and UBR2 through a transcriptional mechanism, we analysed the mRNA levels and found that activin A up‐regulated the *atrogin1* and *UBR2* mRNA, which was blocked by either SB202190 (*Figure* [2](#jcsm12145-fig-0002){ref-type="fig"}D) or p38β MAPK knockdown (*Figure* [2](#jcsm12145-fig-0002){ref-type="fig"}E). Therefore, activin A up‐regulates atrogin1 and UBR2 gene expression via the activation of p38β MAPK and up‐regulates MuRF1 via a third signalling pathway other than p38β MAPK‐ or Akt‐mediated signalling.

![Activin A up‐regulates the expression of E3 ubiquitin ligases UBR2 and atrogin1 through the activation of p38β MAPK in C2C12 myotubes. (A) Activin A up‐regulates UBR2 and atrogin1 via p38 MAPK. C2C12 myotubes were treated with activin A with or without the presence of SB202190 for 8 h. Cell lysate was analysed by Western blotting. (B) JNK inhibition does not affect activin A up‐regulation of UBR2 and atrogin1. (C) Activin A up‐regulates UBR2 and atrogin1 via p38β MAPK. C2C12 myoblasts transfected with small interfering RNA (siRNA) as indicated were differentiated for 96 h to form myotubes and then treated with activin A for 8 h. E3 levels in cell lysate were determined by Western blotting. (D) Activin A up‐regulates *UBR2* and *atrogin1* gene expression via p38 MAPK. C2C12 myotubes were treated as described in (A) for 4 h. Real‐time PCR was performed to determine mRNA levels of the two genes. (E) Activin A up‐regulation of the *UBR2* and *atrogin1* gene requires p38β MAPK. C2C12 myoblasts transfected with siRNA as indicated were differentiated for 96 h to form myotubes and then treated with activin A for 4 h. Real‐time PCR was performed to determine mRNA levels of the two genes. Data were analysed with analysis of variance. Asterisk (\*) denotes a difference (*P* \< 0.05).](JCSM-8-202-g002){#jcsm12145-fig-0002}

In addition to activating the UPP, ActRIIB activation also leads to autophagy activation.[40](#jcsm12145-bib-0040){ref-type="ref"} However, the signalling pathway through which ActRIIB activates autophagy is undefined. Activation of p38 MAPK[15](#jcsm12145-bib-0015){ref-type="ref"} or inactivation of Akt[41](#jcsm12145-bib-0041){ref-type="ref"} activates autophagy in muscle cells. However, the fact that Akt is activated by activin A precludes its involvement in mediating autophagy activation by ActRIIB. Therefore, we examined whether activin A activates autophagy via p38 MAPK. We monitored autophagy activity by analysing levels of LC3‐II, the marker of autophagosome formation,[42](#jcsm12145-bib-0042){ref-type="ref"} and observed that activin A treatment of myotubes for 8 h increased LC3‐II levels, which was blocked by SB202190 (*Figure* [3](#jcsm12145-fig-0003){ref-type="fig"}A), but not by SP600125 (*Figure* [3](#jcsm12145-fig-0003){ref-type="fig"}B). Further, activin A effect on LC3 levels was blocked by p38β MAPK knockdown specifically (*Figure* [3](#jcsm12145-fig-0003){ref-type="fig"}C). Therefore, ActRIIB activation in myotubes stimulates autophagy activity via p38β MAPK.

![Activin A induces autophagy activation in C2C12 myotubes via the activation of p38β MAPK. Cell lysates derived from *Figure* 2A--C were further analysed for LC3 levels by Western blotting. LC3‐II levels were normalized to α‐tubulin. Asterisk (\*) denotes a difference (*P* \< 0.05) between the bracketed columns as determined by analysis of variance.](JCSM-8-202-g003){#jcsm12145-fig-0003}

Activin A induces myotube atrophy by activating p38β MAPK {#jcsm12145-sec-0017}
---------------------------------------------------------

To assess whether p38β MAPK is critical to activin A‐induced myotube atrophy, we treated myotubes with activin A for 72 h and observed that activin A induced MHC loss, which was blocked by SB202190 (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}A). As expected, SP600125 failed to prevent the reduction of MHC induced by activin A (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}B). Knockdown of p38β MAPK spared MHC loss (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}C). Further, by measuring the diameter of myotubes, we observed that activin A induced loss of myotube mass, which was blocked by SB202190 (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}D), but not SP600125 (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}E), and by knockdown of p38β MAPK (*Figure* [4](#jcsm12145-fig-0004){ref-type="fig"}F). Therefore, activin A‐induced activation of p38β MAPK is critical to the development of myofibrillar protein loss and myotube atrophy.

![Activin A induces myotube atrophy by activating p38β MAPK. (A) Activin A induces myosin heavy chain (MHC) loss through the activation of p38 MAPK. C2C12 myotubes were treated with activin A for 72 h with or without the presence of SB202190. MHC in cell lysate was analysed by Western blotting. (B) Activin A‐induced MHC loss is not blocked by JNK inhibition. C2C12 myotubes were treated with activin A for 72 h with or without the presence of SP600125. MHC in cell lysate was analysed by Western blotting. (C) Activin A induces MHC loss through the activation of p38β MAPK. Myoblasts were transfected with siRNA as indicated and differentiated into myotubes for 96 h. Then, myotubes were treated with activin A for 72 h. MHC in cell lysate was analysed by Western blotting. (D--F) Activin A induces myotube atrophy through the activation of p38β MAPK. Myotubes derived from (A--C) were subjected to immunofluorescence staining of MHC. Diameter of myotubes was then determined as described in [Methods](#jcsm12145-sec-0002){ref-type="sec"} section. Bar = 50 µm. Asterisk (\*) denotes a difference (*P* \< 0.05) between the bracketed columns as determined by analysis of variance.](JCSM-8-202-g004){#jcsm12145-fig-0004}

Activin A‐induced muscle catabolic response in mice is dependent on p38β MAPK {#jcsm12145-sec-0018}
-----------------------------------------------------------------------------

To verify whether p38β MAPK signalling in muscle mediates the catabolic response to activin A *in vivo*, we administered activin A systemically to mice (i.p. 100 µg/kg, extrapolated from the *in vitro* dose used) and examined markers of the catabolic pathways in TA in 8 h. Similar to myotubes, activin A administration resulted in activation of p38 MAPK (*Figure* [5](#jcsm12145-fig-0005){ref-type="fig"}A) as well as C/EBPβ and Akt (*Figure* [5](#jcsm12145-fig-0005){ref-type="fig"}B) in control mice (p38β^f/f^) *in vivo*. In addition, we observed up‐regulation of atrogin1, UBR2, and MuRF1 and increase in LC3‐II in control mice. Pre‐treating mice with SB202190 blocked C/EBPβ activation, atrogin1, and UBR2 up‐regulation as well as LC3‐II increase, but not Akt activation and MuRF1 up‐regulation. Further, we administered activin A to mice with muscle‐specific knockout of p38β MAPK (p38β MKO) to study its *in vivo* effects. In the absence of p38β MAPK, activin A failed to induce C/EBPβ activation, atrogin1, and UBR2 up‐regulation as well as LC3‐II increase. On the other hand, Akt activation and MuRF1 up‐regulation were not affected by p38β MAPK knockout (*Figure* [5](#jcsm12145-fig-0005){ref-type="fig"}B). To determine whether activin A promotes the gene expression of atrogin1, UBR2, and LC3b *in vivo*, we further analysed their mRNA levels in TA. We observed increase in the three mRNAs by activin A, which was abolished by SB202190 or p38β MAPK knockout (*Figure* [5](#jcsm12145-fig-0005){ref-type="fig"}C). Therefore, we conclude that activin A activates muscle catabolic pathways *in vivo* primarily through the activation of p38β MAPK.

![Activin A‐induced muscle catabolic response in mice is dependent on p38β MAPK. (A) Systemic administration of activin A activates p38 MAPK in mouse muscle. Activin A (or vehicle phosphate‐buffered saline (PBS)) was injected i.p. (100 µg/kg) to 7‐week‐old male control mice (p38β^f/f^). In 8 h, the tibialis anterior (TA) muscle was collected for analysis by Western blotting. (B) Activin A‐induced catabolic response in mouse muscle is abolished by inhibition or knockout of p38β MAPK. Activin A (or vehicle PBS) was injected i.p. (100 µg/kg) to 7‐week‐old male control mice (p38β^f/f^) and mice with muscle‐specific knockout of p38β MAPK (p38β MKO). When indicated, SB202190 was i.p. injected (5 mg/kg) 30 min prior to activin A injection. In 8 h, the TA muscle was collected for analyses by Western blotting. (C) Activin A acts through p38β MAPK to up‐regulate the gene transcription of UBR2, atrogin1, and LC3b in mouse muscle. TA samples obtained were further analysed with real‐time PCR for mRNA levels of the three genes. Asterisk (\*) denotes a difference (*P* \< 0.05) between the bracketed columns as determined by analysis of variance.](JCSM-8-202-g005){#jcsm12145-fig-0005}

Discussion {#jcsm12145-sec-0019}
==========

The current study reveals that ActRIIB activation by activin A induces muscle catabolism primarily through the activation of p38β MAPK‐mediated catabolic signalling that activates the UPP and the ALP. This finding is important because of the current confusion on the signalling mechanism of ActRIIB‐mediated muscle catabolism, given that ActRIIB is widely considered as a therapeutic target for various forms of muscle atrophy. Previous studies demonstrated the catabolic effect of activin A on muscle by systemically overexpressing activin A in mice[43](#jcsm12145-bib-0043){ref-type="ref"} where levels of activin A that muscles were exposed to was uncontrolled. By administrating activin A, we show here that activin A provokes a catabolic response in a dose comparable with that of other catabolic cytokines such as TNFα or IL‐6 *in vitro* and *in vivo*,[16](#jcsm12145-bib-0016){ref-type="ref"}, [44](#jcsm12145-bib-0044){ref-type="ref"} which puts activin A in the same pathological context as other known mediators of muscle wasting.

The signalling mechanism through which ActRIIB mediates accelerated muscle protein degradation is more complex than originally thought. Previously, the Smad family of transcription factors and Akt‐mediated signalling were considered as the major mediators of the catabolic action of ActRIIB in skeletal muscle.[25](#jcsm12145-bib-0025){ref-type="ref"} However, recent data refuted a key role of Smads in ActRIIB‐mediated muscle atrophy,[33](#jcsm12145-bib-0033){ref-type="ref"} and our present data suggest a non‐essential role of Akt in this process. Instead, we obtained *in vitro* and *in vivo* evidence that p38β MAPK is required for ActRIIB‐mediated activation of catabolic pathways in muscle.

Although we showed previously that p38β MAPK up‐regulates atrogin1 and UBR2,[8](#jcsm12145-bib-0008){ref-type="ref"}, [23](#jcsm12145-bib-0023){ref-type="ref"} this is the first time we demonstrate that p38β MAPK also mediates the activation of autophagy. It is known for several years that p38 MAPK mediates autophagy activation in response to pathogen challenges as part of the innate immune response.[45](#jcsm12145-bib-0045){ref-type="ref"} Similarly, such pathogen as LPS activates autophagy in skeletal muscle cells via the activation of p38 MAPK.[15](#jcsm12145-bib-0015){ref-type="ref"} However, the specific isoform of p38 MAPK that mediates autophagy activation was unknown. We present *in vitro* and *in vivo* evidence in the current study that activin A induces autophagy activation in muscle cells via p38β MAPK. This finding identifies an ActRIIB‐activated signalling pathway in muscle that coordinately activates the two major cellular protein degradation pathways, the UPP and the ALP, and allows intervention of ActRIIB‐mediated activation of both pathways by targeting abnormal activation of a single kinase---p38β MAPK.

While we confirmed that atrogin1 and UBR2 up‐regulation by activin A was mediated by p38β MAPK but not Akt, we also showed that MuRF1 up‐regulation by activin A was dependent on neither p38 MAPK nor Akt. Sriram *et al.* showed previously that MuRF1 is up‐regulated by ActRIIB agonist myostatin independent of Smad3 or NF‐kB.[33](#jcsm12145-bib-0033){ref-type="ref"} Thus, up‐regulation of MuRF1 by activin A may be mediated by an unknown mechanism. MuRF1 up‐regulation has been considered critical to muscle atrophy induced by diverse stimuli because of its direct role in targeting myofibrillar proteins including MHC for degradation.[46](#jcsm12145-bib-0046){ref-type="ref"}, [47](#jcsm12145-bib-0047){ref-type="ref"} However, in the present study, we observed that perturbation of p38β MAPK blocked activin A‐induced MHC loss and myotube atrophy without affecting the up‐regulation of MuRF1. Therefore, MuRF1 appears not essential for the degradation of MHC and myotube atrophy induced by activin A. Thus, activin A‐induced degradation of MHC is likely mediated by unknown mechanisms. In fact, MuRF1 is not up‐regulated in cachectic muscle of certain tumour‐bearing mice with severe MHC loss,[24](#jcsm12145-bib-0024){ref-type="ref"} which supports the presence of unknown mechanisms that mediate MHC degradation associated with cancer cachexia.

As a stress‐activated kinase, muscle p38 MAPK is activated by many catabolic stimuli in addition to ActRIIB agonists, including cancer,[24](#jcsm12145-bib-0024){ref-type="ref"} LPS,[15](#jcsm12145-bib-0015){ref-type="ref"}, [17](#jcsm12145-bib-0017){ref-type="ref"} pro‐inflammatory cytokines,[16](#jcsm12145-bib-0016){ref-type="ref"} oxidative stress, and dexamethasone.[17](#jcsm12145-bib-0017){ref-type="ref"} Thus, p38β MAPK appears to be a central mediator of muscle wasting associated with various disease conditions and therefore a common therapeutic target for muscle wasting associated with various diseases. On the other hand, Akt, FoxOs, and Smads appear to be critical to muscle atrophy associated with physiological stress, such as fasting, disuse, and denervation as shown by other investigators.[13](#jcsm12145-bib-0013){ref-type="ref"}, [14](#jcsm12145-bib-0014){ref-type="ref"} Considering that p38α MAPK is responsible for many of the functions of p38 MAPK ranging from responding to inflammatory stimuli[48](#jcsm12145-bib-0048){ref-type="ref"} and mediating ischaemic preconditioning in the heart[49](#jcsm12145-bib-0049){ref-type="ref"} to regulating myogenesis in striated muscles,[18](#jcsm12145-bib-0018){ref-type="ref"}, [50](#jcsm12145-bib-0050){ref-type="ref"} developing p38β MAPK‐specific inhibitors is a promising strategy for combating cachectic muscle wasting associated with various diseases.
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